Le Lézard
Classified in: Science and technology, Business

Gentoo Media - Mandatory notification of trade


ST JULIANS, Malta, Nov. 13, 2024 /PRNewswire/ -- MJ Foundation Fundacja Rodzinna, a company related to Mateusz Juroszek, Board Member and primary insider of Gentoo Media Inc. (Gentoo) has today acquired 115,604 shares in Gentoo at a price of SEK 24,996 per share. After this transaction, close associates of Mateusz Juroszek hold 24,027,766 shares in Gentoo.

This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

For further information, contact:
Tore Formo, Group CFO, [email protected], +47 91668678

About Gentoo Media

Gentoo Media is a market-leading affiliate connecting operators and players in the online gambling and sports betting industry. Gentoo Media offers an array of iGaming affiliate solutions, such as paid marketing expertise and quality traffic through our prominent industry sites including AskGamblers, Time2Play, CasinoTopsOnline, WSN and Casinomeister. In 2024, Gentoo Media (formerly GiG Media) became Gentoo Media Inc. following a legal split separating the Media and Platform and Sportsbook business in Gaming Innovation Group (GiG) into two independently listed companies. Gentoo Media Inc. is dual listed on the Oslo Stock Exchange (ticker "G2MNO") and Nasdaq Stockholm (ticker "G2M"). www.gentoomedia.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/gentoo-media-inc/r/gentoo-media---mandatory-notification-of-trade,c4066199

SOURCE Gentoo Media Inc


These press releases may also interest you

at 15:30
Tony Van Heugten, CTO of e-Vision Smart Optics, Inc., inducted in the 2024 Florida Inventors Hall of Fame
Anthony "Tony" Van Heugten, the Chief Technology...

at 15:05
Merck's Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma
Merck , known as MSD outside of the United States and Canada, today announced the first presentation of data from the Phase 2 waveLINE-007 trial evaluating zilovertamab vedotin, Merck's investigational antibody drug conjugate (ADC) that targets...

at 15:00
AbbVie Announces Emotional Impact Report on Mental Health of Underrepresented CLL Cancer Patients
AbbVie announced groundbreaking results today from its latest Emotional Impact Report (EIR), a patient survey that provides an understanding of the mental...

at 12:55
Vertex Presents Positive Long-Term Data On CASGEVYtm (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update
Vertex Pharmaceuticals Incorporated today announced longer-term data for CASGEVYtm (exagamglogene autotemcel) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the...

at 12:35
Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH
Kite, a Gilead Company , today announced findings from three new analyses for Yescarta® (axicabtagene ciloleucel) that demonstrate improved outcomes for people living with relapsed or refractory (R/R) large B-cell lymphoma (LBCL), which were...

at 12:35
Five-Year Results Confirm Genentech's Polivy Combination Therapy as New Standard of Care for Previously Untreated Aggressive Lymphoma
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today data from a five-year follow-up of the pivotal Phase III POLARIX study evaluating Polivy® (polatuzumab vedotin-piiq) in combination with Rituxan® (rituximab),...

More news about Science and technology...


News published on and distributed by: